Pomerantz Law Firm Investigates Securities Fraud Claims Against argenx SE

What's Happening?

Pomerantz LLP has initiated an investigation into potential securities fraud or other unlawful business practices by argenx SE and certain of its officers and directors. This action follows an alert issued by the U.S. Food and Drug Administration (FDA) on June 30, 2025, regarding argenx's Vyvgart Hytrulo product. The FDA's alert highlighted a potential risk of severe worsening of chronic inflammatory demyelinating polyradiculoneuropathy associated with the treatment, based on reports from the FDA Adverse Event Reporting System. Following this announcement, argenx's American Depositary Share (ADS) price dropped by $8.92, closing at $551.22 per ADS, marking a 1.59% decrease. Pomerantz LLP, known for its expertise in corporate, securities, and antitrust class litigation, is encouraging affected investors to contact them for potential class action participation.

Why It's Important?

The investigation by Pomerantz LLP into argenx SE is significant as it underscores the potential legal and financial repercussions for the company and its investors. The FDA's alert about Vyvgart Hytrulo raises concerns about the safety of the product, which could lead to regulatory actions affecting the company's market position and financial performance. Investors in argenx SE may face financial losses if the allegations of securities fraud are substantiated, potentially leading to a class action lawsuit. This situation highlights the critical role of regulatory bodies like the FDA in safeguarding public health and investor interests, as well as the importance of transparency and compliance in corporate governance.

What's Next?

The next steps involve the FDA's ongoing evaluation of the need for regulatory action concerning Vyvgart Hytrulo. Depending on the outcome, argenx SE may face further scrutiny and potential legal challenges. Investors and stakeholders will be closely monitoring the situation for any developments that could impact the company's operations and stock performance. Pomerantz LLP's investigation may lead to a class action lawsuit if sufficient evidence of securities fraud is found, which could result in financial restitution for affected investors.